Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

The NCI Transcriptional Pharmacodynamics Workbench: A Tool to Examine Dynamic Expression Profiling of Therapeutic Response in the NCI-60 Cell Line Panel.

Monks A, Zhao Y, Hose C, Hamed H, Krushkal J, Fang J, Sonkin D, Palmisano A, Polley EC, Fogli LK, Konaté MM, Miller SB, Simpson MA, Voth AR, Li MC, Harris E, Wu X, Connelly JW, Rapisarda A, Teicher BA, Simon R, Doroshow JH.

Cancer Res. 2018 Dec 15;78(24):6807-6817. doi: 10.1158/0008-5472.CAN-18-0989. Epub 2018 Oct 24.

PMID:
30355619
2.

Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents.

O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJ Jr, Kohn KW.

Cancer Res. 1997 Oct 1;57(19):4285-300.

3.

CellMiner: a relational database and query tool for the NCI-60 cancer cell lines.

Shankavaram UT, Varma S, Kane D, Sunshine M, Chary KK, Reinhold WC, Pommier Y, Weinstein JN.

BMC Genomics. 2009 Jun 23;10:277. doi: 10.1186/1471-2164-10-277.

4.

Integrating global gene expression and radiation survival parameters across the 60 cell lines of the National Cancer Institute Anticancer Drug Screen.

Amundson SA, Do KT, Vinikoor LC, Lee RA, Koch-Paiz CA, Ahn J, Reimers M, Chen Y, Scudiero DA, Weinstein JN, Trent JM, Bittner ML, Meltzer PS, Fornace AJ Jr.

Cancer Res. 2008 Jan 15;68(2):415-24. doi: 10.1158/0008-5472.CAN-07-2120.

5.

Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters.

Okabe M, Szakács G, Reimers MA, Suzuki T, Hall MD, Abe T, Weinstein JN, Gottesman MM.

Mol Cancer Ther. 2008 Sep;7(9):3081-91. doi: 10.1158/1535-7163.MCT-08-0539.

6.

The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity.

Holbeck SL, Camalier R, Crowell JA, Govindharajulu JP, Hollingshead M, Anderson LW, Polley E, Rubinstein L, Srivastava A, Wilsker D, Collins JM, Doroshow JH.

Cancer Res. 2017 Jul 1;77(13):3564-3576. doi: 10.1158/0008-5472.CAN-17-0489. Epub 2017 Apr 26.

7.

Impact of EGFR gene polymorphisms on anticancer drug cytotoxicity in vitro.

Puyo S, Le Morvan V, Robert J.

Mol Diagn Ther. 2008;12(4):225-34.

PMID:
18652519
8.

RNA Sequencing of the NCI-60: Integration into CellMiner and CellMiner CDB.

Reinhold WC, Varma S, Sunshine M, Elloumi F, Ofori-Atta K, Lee S, Trepel JB, Meltzer PS, Doroshow JH, Pommier Y.

Cancer Res. 2019 Jul 1;79(13):3514-3524. doi: 10.1158/0008-5472.CAN-18-2047. Epub 2019 May 21.

PMID:
31113817
9.

Functional categories associated with clusters of genes that are co-expressed across the NCI-60 cancer cell lines.

Zeeberg BR, Reinhold W, Snajder R, Thallinger GG, Weinstein JN, Kohn KW, Pommier Y.

PLoS One. 2012;7(1):e30317. doi: 10.1371/journal.pone.0030317. Epub 2012 Jan 24.

10.

Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel.

Shen L, Kondo Y, Ahmed S, Boumber Y, Konishi K, Guo Y, Chen X, Vilaythong JN, Issa JP.

Cancer Res. 2007 Dec 1;67(23):11335-43.

11.

Involvement of gene polymorphisms of the folate pathway enzymes in gene expression and anticancer drug sensitivity using the NCI-60 panel as a model.

Charasson V, Hillaire-Buys D, Solassol I, Laurand-Quancard A, Pinguet F, Le Morvan V, Robert J.

Eur J Cancer. 2009 Sep;45(13):2391-401. doi: 10.1016/j.ejca.2009.05.013. Epub 2009 Jun 6.

PMID:
19501504
12.

The NCI-60 Methylome and Its Integration into CellMiner.

Reinhold WC, Varma S, Sunshine M, Rajapakse V, Luna A, Kohn KW, Stevenson H, Wang Y, Heyn H, Nogales V, Moran S, Goldstein DJ, Doroshow JH, Meltzer PS, Esteller M, Pommier Y.

Cancer Res. 2017 Feb 1;77(3):601-612. doi: 10.1158/0008-5472.CAN-16-0655. Epub 2016 Dec 6.

13.

The NRF2-mediated oxidative stress response pathway is associated with tumor cell resistance to arsenic trioxide across the NCI-60 panel.

Liu Q, Zhang H, Smeester L, Zou F, Kesic M, Jaspers I, Pi J, Fry RC.

BMC Med Genomics. 2010 Aug 13;3:37. doi: 10.1186/1755-8794-3-37.

14.

Concordance of gene expression and functional correlation patterns across the NCI-60 cell lines and the Cancer Genome Atlas glioblastoma samples.

Zeeberg BR, Kohn KW, Kahn A, Larionov V, Weinstein JN, Reinhold W, Pommier Y.

PLoS One. 2012;7(7):e40062. doi: 10.1371/journal.pone.0040062. Epub 2012 Jul 26.

15.

Web-based tools for mining the NCI databases for anticancer drug discovery.

Fang X, Shao L, Zhang H, Wang S.

J Chem Inf Comput Sci. 2004 Jan-Feb;44(1):249-57.

PMID:
14741034
16.

Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen.

Taverna P, Liu L, Hanson AJ, Monks A, Gerson SL.

Cancer Chemother Pharmacol. 2000;46(6):507-16.

PMID:
11138465
17.

GDA, a web-based tool for Genomics and Drugs integrated analysis.

Caroli J, Sorrentino G, Forcato M, Del Sal G, Bicciato S.

Nucleic Acids Res. 2018 Jul 2;46(W1):W148-W156. doi: 10.1093/nar/gky434.

18.

Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines.

Holbeck SL, Collins JM, Doroshow JH.

Mol Cancer Ther. 2010 May;9(5):1451-60. doi: 10.1158/1535-7163.MCT-10-0106. Epub 2010 May 4.

19.
20.

Molecular determinants of the cytotoxicity of platinum compounds: the contribution of in silico research.

Vekris A, Meynard D, Haaz MC, Bayssas M, Bonnet J, Robert J.

Cancer Res. 2004 Jan 1;64(1):356-62.

Supplemental Content

Support Center